Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.10B | 1.01B | 771.48M | 717.89M | 685.87M | 666.15M |
Gross Profit | 195.43M | 47.17M | -3.78M | 5.18M | 67.54M | 80.89M |
EBITDA | 160.41M | 191.45M | 96.81M | 55.86M | 82.65M | 61.55M |
Net Income | 15.09M | -21.41M | -28.45M | -38.80M | 19.95M | -716.00K |
Balance Sheet | ||||||
Total Assets | 2.05B | 1.81B | 1.71B | 1.76B | 1.75B | 1.79B |
Cash, Cash Equivalents and Short-Term Investments | 179.92M | 64.91M | 61.32M | 4.15M | 3.89M | 3.80M |
Total Debt | 4.30M | 3.84M | 71.07M | 113.32M | 153.41M | 248.54M |
Total Liabilities | 2.07B | 1.84B | 1.67B | 1.68B | 1.61B | 1.67B |
Stockholders Equity | -17.48M | -22.89M | 38.39M | 79.01M | 141.97M | 127.79M |
Cash Flow | ||||||
Free Cash Flow | 241.70M | 186.57M | 53.73M | 67.60M | 87.75M | 87.94M |
Operating Cash Flow | 309.02M | 252.30M | 105.16M | 114.79M | 105.03M | 127.23M |
Investing Cash Flow | -103.95M | -136.59M | 6.58M | -48.62M | 7.50M | -37.91M |
Financing Cash Flow | -111.74M | -112.12M | -43.17M | -62.39M | -119.47M | -93.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | AU$2.30B | 152.30 | -276.16% | 2.12% | 25.38% | ― | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
$2.88B | 22.01 | 6.45% | 2.46% | ― | ― | ||
€322.11M | ― | -4.46% | ― | ― | ― | ||
$5.42B | 1,144.55 | 0.52% | 2.00% | ― | ― | ||
73 Outperform | AU$12.83B | 23.44 | 6.86% | 3.29% | 10.15% | 6.20% |
Regis Healthcare Limited has acknowledged the Australian Government’s decision to delay the commencement of the new Aged Care Act 2024 from July 1, 2025, to November 1, 2025. This postponement affects the implementation of funding reforms outlined in the Act, potentially impacting the company’s operations and planning. Regis has committed to keeping stakeholders informed as further details emerge, maintaining transparency in line with its disclosure obligations.
The most recent analyst rating on (AU:REG) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.
Ashburn Pty Ltd, acting as trustee for the Dorman Family Trust, has reduced its stake in Regis Healthcare Ltd. by selling 15 million fully paid ordinary shares, decreasing its voting power from 21.40% to 16.40%. This change in shareholding could impact the company’s shareholder dynamics and influence future decision-making processes.
The most recent analyst rating on (AU:REG) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.
Regis Healthcare Ltd. has released a presentation highlighting its current activities and financial performance. The company emphasizes the use of non-IFRS financial measures to better reflect its underlying performance. The presentation includes forward-looking statements subject to various risks and uncertainties, including regulatory changes and staffing challenges. Stakeholders are advised to consider these factors when evaluating the company’s future performance.